Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-OncoACP3 PET imaging in prostate cancer
NCT06840535Phase 1Completed
- Sponsor
- Philogen
- Start
- Apr 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-Onco-ACP3 (2 cohorts), sponsored by Philogen. Primary endpoints: Effective dose equivalent at 1 day, Effective dose absorbed doses at 1 day and 2 more. Started Apr 2025; status: completed.
02
Drugs
68Ga-Onco-ACP3
Beyond the preview
Go deeper on NCT06840535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06840535.